Private Vista LLC Maintains Stake in Stryker Corporation (NYSE:SYK)

Private Vista LLC held its position in Stryker Corporation (NYSE:SYK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,800 shares of the medical technology company’s stock at the end of the first quarter. Private Vista LLC’s holdings in Stryker Corporation were worth $655,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC increased its position in Stryker Corporation by 600.6% in the first quarter. SG Americas Securities LLC now owns 412,340 shares of the medical technology company’s stock valued at $54,285,000 after buying an additional 353,486 shares during the last quarter. Swiss National Bank increased its position in Stryker Corporation by 22.1% in the first quarter. Swiss National Bank now owns 1,502,071 shares of the medical technology company’s stock valued at $197,748,000 after buying an additional 272,300 shares during the last quarter. Pictet Asset Management Ltd. increased its position in Stryker Corporation by 34.0% in the first quarter. Pictet Asset Management Ltd. now owns 978,677 shares of the medical technology company’s stock valued at $128,843,000 after buying an additional 248,476 shares during the last quarter. Fundsmith LLP increased its position in Stryker Corporation by 4.6% in the first quarter. Fundsmith LLP now owns 5,175,453 shares of the medical technology company’s stock valued at $681,348,000 after buying an additional 226,057 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its position in Stryker Corporation by 462.7% in the first quarter. BNP Paribas Arbitrage SA now owns 252,230 shares of the medical technology company’s stock valued at $33,206,000 after buying an additional 207,409 shares during the last quarter. Institutional investors and hedge funds own 74.25% of the company’s stock.

Stryker Corporation (SYK) opened at 144.81 on Tuesday. The stock has a market cap of $54.12 billion, a price-to-earnings ratio of 32.54 and a beta of 0.79. The stock’s 50 day moving average price is $140.23 and its 200 day moving average price is $130.49. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $145.99.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.90 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.33%. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.24 EPS. On average, analysts forecast that Stryker Corporation will post $6.43 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 31st. Investors of record on Friday, June 30th will be issued a $0.425 dividend. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.17%. Stryker Corporation’s dividend payout ratio is presently 38.20%.

TRADEMARK VIOLATION WARNING: “Private Vista LLC Maintains Stake in Stryker Corporation (NYSE:SYK)” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://sportsperspectives.com/2017/07/18/private-vista-llc-maintains-stake-in-stryker-corporation-nysesyk.html.

Several research analysts have weighed in on SYK shares. Needham & Company LLC restated a “sell” rating on shares of Stryker Corporation in a research note on Wednesday, April 26th. Morgan Stanley increased their target price on Stryker Corporation from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, June 21st. Jefferies Group LLC reiterated a “hold” rating and set a $132.00 target price on shares of Stryker Corporation in a research report on Thursday, April 13th. Cowen and Company set a $150.00 target price on Stryker Corporation and gave the company an “outperform” rating in a research report on Wednesday, April 26th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $148.00 target price (up from $135.00) on shares of Stryker Corporation in a research report on Saturday, April 29th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $138.36.

In related news, insider Timothy J. Scannell sold 13,322 shares of the business’s stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $135.89, for a total value of $1,810,326.58. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Floyd sold 19,305 shares of the business’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. Insiders sold a total of 40,008 shares of company stock worth $5,669,088 in the last quarter. Company insiders own 7.40% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply